Skip to content

Nutritional Prevention Pilot Trial for Type 1 Diabetes

Trial to Reduce IDDM in the Genetically at Risk (TRIGR): the Pilot Study

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00570102
Acronym
MIP
Enrollment
230
Registered
2007-12-10
Start date
1995-02-28
Completion date
2008-01-31
Last updated
2012-11-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 1 Diabetes Mellitus

Keywords

dietary manipulation, infants, feasibility, Type 1 Diabetes Mellitus, Beta-cell Autoimmunity

Brief summary

The overall objective of the study is to assess whether complete avoidance of cow's milk (CM) proteins, for at least the first 6 months of life, prevents type 1 diabetes (insulin-dependent diabetes mellitus, IDDM) in genetically susceptible children who have a mother, biological father or sibling affected by type 1 diabetes.

Detailed description

Among the environmental factors leading to type 1 diabetes in childhood, the most important are certain viral infections and possibly some dietary factors. Among the latter cow's milk proteins are of special interest. They have been shown to be involved in the pancreatic beta-cell lesion in animal experiments. In humans there are some indications of a role of early exposure to cow's milk proteins as a risk factor for later type 1 diabetes. The hypothesis has not been confirmed, but a randomized, controlled double-blinded intervention trial should provide a definite answer. This study aims at assessing whether one can decrease the future incidence of beta-cell autoimmunity and/or type 1 diabetes in children who have an increased genetic risk for the disease, by administering in infancy after breast feeding until the age of 6-8 months such a formula, in which the cow's milk proteins have been hydrolyzed to smaller peptides. The children in the control group, carrying a similar increased genetic risk, will receive a conventional cow's milk based formula . This project is a pilot multicenter trial comprising 15 hospitals in Finland.

Interventions

DIETARY_SUPPLEMENTA highly hydrolyzed formula

Weaning to a highly hydrolyzed formula, avoidance of all supplemental food containing cow's milk proteins and/or bovine serum albumin up to the age of 6-8 months

DIETARY_SUPPLEMENTA regular cow's milk based formula

Weaning to a regular cow's milk based formula supplemented with 20% of the highly hydrolyzed formula used in arm 1 to make the study formulas similar in smell and taste, avoidance of all supplemental food containing cow's milk proteins and/or bovine serum albumin

Sponsors

Academy of Finland
CollaboratorOTHER
European Union
CollaboratorOTHER
Juvenile Diabetes Research Foundation
CollaboratorOTHER
Diabetes Research Foundation, Finland
CollaboratorOTHER
Novo Nordisk A/S
CollaboratorINDUSTRY
University of Helsinki
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
1 Days to 7 Days
Healthy volunteers
Yes

Inclusion criteria

* the participant must have a mother, biological father or sibling with type 1 diabetes * the participant must carry a susceptible HLA genotype(HLA-DQB1\*02 and/or DQB1\*0302 without protective alleles (DQB1\*0301, \*0602 and \*0603)

Exclusion criteria

* no telephone * no accessibility to any of the research centers * inability of parents to understand the study and instructions * unwillingness/inability to feed the infant CM-containing food for any reason (e.g. religious, cultural reasons) * gestational age less than 36 weeks * Any severe illness such as chromosomal abnormalities, congenital malformations, respiratory failure, enzyme deficiencies of the newborn. * the newborn infant has received any cow's milk-based product prior to randomization

Design outcomes

Primary

MeasureTime frame
Positivity for two or more diabetes-associated autoantibodies and/or clinical type 1 diabetes10 years

Countries

Finland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 30, 2026